Pulmonx Corp
NASDAQ:LUNG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pulmonx Corp
Stock-Based Compensation
Pulmonx Corp
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pulmonx Corp
NASDAQ:LUNG
|
Stock-Based Compensation
$21.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
46%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Stock-Based Compensation
$31.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Stock-Based Compensation
$55.8m
|
CAGR 3-Years
16%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Stock-Based Compensation
$185.9m
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
13%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Stock-Based Compensation
$85.6m
|
CAGR 3-Years
43%
|
CAGR 5-Years
43%
|
CAGR 10-Years
46%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Stock-Based Compensation
$43.5m
|
CAGR 3-Years
34%
|
CAGR 5-Years
25%
|
CAGR 10-Years
35%
|
|
Pulmonx Corp
Glance View
Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
See Also
What is Pulmonx Corp's Stock-Based Compensation?
Stock-Based Compensation
21.2m
USD
Based on the financial report for Dec 31, 2025, Pulmonx Corp's Stock-Based Compensation amounts to 21.2m USD.
What is Pulmonx Corp's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 5Y
46%
Over the last year, the Stock-Based Compensation growth was -7%. The average annual Stock-Based Compensation growth rates for Pulmonx Corp have been 9% over the past three years , 46% over the past five years .
